Accellix on LinkedIn: Galapagos Partners with Blood Centers of America to Decentralize CAR-T… (2024)

The FDA has issued a new guidance document outlining safety testing recommendations for allogeneic cells used in cell-based therapeutic products to support an Investigational New Drug Application (IND) or a Biologics License Application (BLA). Now more than ever, fast and accurate cell characterization is essential. Discover how Accellix's automated flow cytometry platform can revolutionize your cell therapy QC workflows, delivering rapid cell phenotyping in just 30 minutes. https://www.accellix.com/https://lnkd.in/d2MgNDT5

6

A huge milestone for gene editing! Prime Medicine, Inc. has received the first-ever IND clearance from the FDA for a prime editing drug to treat chronic granulomatous disease (CGD). PM359 consists of autologous hematopoietic stem cells modified ex vivo using prime editors designed to correct a high percentage of cells with the p47phox mutation.https://lnkd.in/gWRHV_Bj

5

#ICYMI: Download the Accellix poster from #CYTO2024 on our website: https://lnkd.in/gsEH4fKKExplore the data generated in collaboration with Triumvira Immunologics, Inc. demonstrating the capabilities of our automated flow cytometer platform:▪ Detect and resolve all the major immune cell lineages (T, B and NK cells) with high reproducibility and low inter-operator variability ▪ Cell frequencies and yields were comparable to conventional cytometers and cell counters

14

Exciting news in gene therapy! Pfizer’s Beqvez becomes the second gene therapy approved by the FDA for hemophilia B. With several other gene therapies in their pipeline including one for hemophilia A, Pfizer is continuing to drive progress in the field. https://lnkd.in/dGnmsyTp

12

Our #flowcytometry experts Suha Kasey and Jacob van Vloten are counting down the days until #CYTO2024 in beautiful Edinburgh, Scotland! Don't miss Accellix's poster presentation on May 7th, 6:00 – 7:00pm at Board #153, to learn about "The Accellix Automated Flow Cytometer: Reproducible and Efficient Phenotyping for Cell Therapy Manufacturing" in collaboration with Triumvira Immunologics, Inc. See you there!

13

🧬National DNA Day celebrates the discovery of DNA's double helix in 1953 and the completion of the Human Genome Project in 2003. These important milestones are foundational to many exciting advancements and innovations in science and medicine. Here's to the scientists and visionaries like James Watson, Francis Crick, and Rosalind Franklinwho inspire us to build on their legacy and continue to push boundaries and forge new paths ahead. #NationalDNADay

8

Bristol Myers Squibb has signed a $380 million supply deal with manufacturer Cellares, which will provide access to their automated Cell Shuttle manufacturing platform. This partnership promises to bolster BMS' CAR-T cell therapy production, potentially speeding up turnaround times and meeting the growing demand for Breyanzi and Abecma, as well as future candidates.#cartcelltherapy https://lnkd.in/gSFaTVyp

31

FDA announced the establishment of the CDER Center for Clinical Trial Innovation (C3TI). C3TI’s goal is to promote clinical trial innovations through enhanced communication and collaboration with sponsor companies to positively impact drug development. https://lnkd.in/g4CVV3T4

5

Alliance for Regenerative Medicine's latest Sector Snapshot includes new sector data, anticipated approvals for the 2024 clinical pipeline, and trends in cell therapy development, including a new wave of treatments targeting autoimmune diseases. It's a must-read for anyone involved in advanced therapies!https://lnkd.in/gb6-ghHE

3